Hyong Kim Sells Shares of Alignment Healthcare, Inc. (ALHC)

Hyong Kim, the Chief Medical Officer of Alignment Healthcare, Inc. (NasdaqGS: ALHC), sold 35,951 shares of the company on June 12, 2026. The shares were sold at an average price of $19.86, totaling approximately $713,986.86. This transaction was planned under a Rule 10b5-1 trading plan.

Other Institutional Activity in Alignment Healthcare

Wellington Management Group grew its holdings in Alignment Healthcare by 3,028,043 shares, ending with 17,098,936 shares valued at about $301 million. Similarly, FMR LLC added 1,236,129 shares, bringing its total to 15,892,064 shares worth approximately $280 million. BlackRock, Inc. increased its position by 363,883 shares, reaching 14,075,197 shares valued at $248 million. T. Rowe Price Investment Management, Inc. also boosted its stake by 503,872 shares, now holding 13,147,656 shares valued at $231 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both established new positions, each holding 9,710,071 and 7,973,663 shares, respectively.

Alignment Healthcare Stock Snapshot

Shares of Alignment Healthcare (NasdaqGS: ALHC) traded near $19.75. The company has a market cap of approximately $4.08 billion and a P/E ratio of 197.5. Its forward P/E stands at 27.34, and the stock has a beta of 1.149. The 52-week range for the stock is between $11.63 and $23.87, with a 50-day moving average of $18.62 and a 200-day moving average of $18.61. The company's current ratio is 1.58, and its debt-to-equity ratio is 159.49.

Recent Earnings

Alignment Healthcare reported revenue of $4.26 billion with a revenue growth rate of 33.3%. The company achieved a net margin of 0.47% and a return on equity of 12.53%. Earnings per share stood at $0.10. The next earnings report is expected on July 30, 2026.

Insider Buying and Selling at Alignment Healthcare, Inc.

On June 12, 2026, Hyong Kim, Chief Medical Officer, sold 35,951 shares at an average price of $19.86. Joseph Konowiecki, EVP of Corporate Affairs, sold 25,000 shares at $21.00 on June 11, 2026. On June 10, 2026, CEO John Kao sold 298,000 shares at $20.36. Earlier, on June 3, 2026, Joseph Konowiecki and Mark Kent, President - MSO, made notable buy transactions, acquiring 122,807 and 87,719 shares respectively.

Analysts Set New Price Targets

On May 26, 2026, Barclays maintained its hold rating on Alignment Healthcare with a price target of $16. UBS also maintained a hold rating with a $22 target on May 1, 2026. Previously, on February 5, 2026, JP Morgan maintained a buy rating with a target of $26. The consensus among analysts is a strong buy recommendation with a mean price target of $24.92 from 13 opinions.

About Alignment Healthcare

Alignment Healthcare, Inc. is a healthcare company focused on providing personalized healthcare solutions for seniors in the United States. It operates through Medicare Advantage plans, aiming to deliver a tailored healthcare experience. Founded in 2013, the company is headquartered in Orange, California, and led by CEO John E. Kao. It employs around 1,849 people.

Bottom Line

Hyong Kim's recent share sale is a planned transaction under a 10b5-1 plan, reflecting strategic financial management. Investors often track insider activities like these to gauge executive confidence in the company's future. While this sale is noteworthy, it's essential to consider the broader context of institutional holdings and analyst perspectives for a comprehensive view of Alignment Healthcare's market position.